<p>Immunocore Holdings PLC 贊助的 ADR（NASDAQ:IMCR - 獲取免費報告）在週五達到了新的 52 周高點。該股最高交易價為 40.71 美元，最後交易價為 39.93 美元，成交量為 5771 股。該股此前收盤價為 40.22 美元。</p>
<h2>華爾街分析師觀點</h2>
<ul>
<li>增長選擇：3 只低成本股票可能會翻倍</li>
</ul>
<p>多位股票分析師最近對該股發佈了報告。摩根士丹利將 Immunocore 的目標價從 34.00 美元上調至 36.00 美元，並在 11 月 10 日的研究報告中給予該公司 “持平” 評級。Guggenheim 於 9 月 18 日星期四開始對 Immunocore 進行覆蓋。他們對該公司給予了 “中性” 評級。HC Wainwright 在 10 月 22 日星期三重申了 “買入” 評級，並對 Immunocore 的目標價設定為 100.00 美元。Weiss Ratings 在 10 月 8 日星期三的報告中重新發布了對 Immunocore 的 “賣出（e+）” 評級。最後，Wall Street Zen 在 11 月 8 日星期六的研究報告中將 Immunocore 的評級從 “持有” 上調至 “買入”。七位投資分析師對該股給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Immunocore 的共識評級為 “適度買入”，平均目標價為 61.00 美元。</p>
<p><strong>閲讀我們關於 Immunocore 的最新報告</strong></p>
<h2>Immunocore 股價下跌 3.2%</h2>
<ul>
<li>3 只快速增長的股票分析師認為價格將翻倍</li>
</ul>
<p>該公司的市值為 19.7 億美元，市盈率為 -68.16，貝塔值為 0.77。該公司的速動比率為 5.97，流動比率為 6.00，債務股本比率為 0.99。該公司的 50 日移動平均線為 35.06 美元，200 日移動平均線為 34.23 美元。</p>
<p>Immunocore（NASDAQ:IMCR - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告每股收益（EPS）為 0.02 美元，超出市場共識預期的 -0.30 美元，超出幅度為 0.32 美元。該公司季度收入為 1.0369 億美元，而分析師預期為 1.3729 億美元。Immunocore 的股本回報率為 -7.67%，淨利潤率為 -7.70%。該公司的收入同比增長 29.2%。在去年同期，該公司每股收益為 0.17 美元。股票分析師預測 Immunocore Holdings PLC 贊助的 ADR 在本年度將發佈 -0.94 美元的每股收益。</p>
<h2>Immunocore 的內部買賣</h2>
<ul>
<li>機構正在購買這 3 只股票，分析師一致認為</li>
</ul>
<p>在相關消息中，內部人士 David M. Berman 於 9 月 12 日星期五出售了 22,532 股 Immunocore 股票。該股票以平均價格 35.67 美元出售，總價值為 803,716.44 美元。此次出售已在與 SEC 的法律文件中披露，文件可在此鏈接查看。10.40% 的股票由公司內部人士持有。</p>
<h2>機構資金流入和流出</h2>
<p>機構投資者最近對該公司的持倉進行了調整。GAMMA Investing LLC 在第三季度將其在 Immunocore 的持倉增加了 51.6%。GAMMA Investing LLC 目前擁有 914 股該公司股票，價值 33,000 美元，此前在上個季度增持了 311 股。DNB Asset Management AS 在第三季度將其在 Immunocore 的持倉增加了 6.4%。DNB Asset Management AS 目前擁有 8,116 股該公司股票，價值 295,000 美元，此前在上個季度增持了 488 股。Virtus Investment Advisers LLC 在第二季度將其在 Immunocore 的持倉增加了 5.3%。Virtus Investment Advisers LLC 目前擁有 12,472 股該公司股票，價值 391,000 美元，此前在上個季度增持了 625 股。Orion Porfolio Solutions LLC 在第二季度將其在 Immunocore 的持倉增加了 4.5%。Orion Porfolio Solutions LLC 目前擁有 23,965 股該公司股票，價值 752,000 美元，此前在此期間增持了 1,031 股。最後，Assetmark Inc. 在第二季度將其在 Immunocore 的持倉增加了 3.7%。Assetmark Inc. 目前擁有 34,958 股該公司股票，價值 1,097,000 美元，此前在上個季度增持了 1,248 股。84.50% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Immunocore 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Immunocore Holdings plc 是一家商業階段的生物技術公司，專注於開發用於治療癌症、感染和自身免疫性疾病的免疫療法。該公司提供 KIMMTRAK，用於治療不可切除或轉移性葡萄膜黑色素瘤的患者。它還開發其他腫瘤學項目，包括正在進行 2/3 期臨牀試驗的 tebentafusp，用於治療晚期皮膚黑色素瘤。</p>
<h2>另請參閲</h2>
<ul>
<li>我們更看好的五隻股票超過 Immunocore</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>加密礦工會轉向 AI 嗎？關於 3 家關鍵參與者的最新消息</li>
<li>股息捕獲策略：你需要知道的事項</li>
<li>Salesforce 股票像彈簧一樣蓄勢待發，準備反彈</li>
<li>什麼是 SEC 備案？</li>
<li>Marvell 的反彈延續：數據中心和 AMZN 芯片推動股價上漲</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Immunocore 嗎？</h2>
<p>在你考慮投資 Immunocore 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Immunocore 並不在名單上。</p>
<p>雖然 Immunocore 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

IMCR

<p>Immunocore Holdings PLC（納斯達克代碼：IMCR）達到了新的 52 周高點，交易價格高達 40.71 美元。分析師的評級各不相同，普遍共識為 “適度買入”，平均目標價為 61.00 美元。該公司報告的收益超出預期，收入同比增長 29.2%。內部人士和機構的活動顯示出顯著的股票交易。Immunocore 開發用於癌症和其他疾病的免疫療法</p>

<p>Shares of Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) reached a new 52-week high on Friday . The stock traded as high as $40.71 and last traded at $39.93, with a volume of 5771 shares. The stock had previously closed at $40.22.</p>
<div class="lb-trans"><p>Immunocore Holdings PLC 贊助的 ADR（NASDAQ:IMCR - 獲取免費報告）在週五達到了新的 52 周高點。該股最高交易價為 40.71 美元，最後交易價為 39.93 美元，成交量為 5771 股。該股此前收盤價為 40.22 美元。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><ul>
<li>Growth Picks: 3 Low-Cost Stocks That Could Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>增長選擇：3 只低成本股票可能會翻倍</li>
</ul>
</div><p>A number of equities analysts recently issued reports on the stock. Morgan Stanley increased their target price on shares of Immunocore from $34.00 to $36.00 and gave the company an &#34;equal weight&#34; rating in a research report on Monday, November 10th. Guggenheim started coverage on shares of Immunocore in a research note on Thursday, September 18th. They issued a &#34;neutral&#34; rating for the company. HC Wainwright reiterated a &#34;buy&#34; rating and issued a $100.00 price objective on shares of Immunocore in a report on Wednesday, October 22nd. Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Immunocore in a report on Wednesday, October 8th. Finally, Wall Street Zen raised Immunocore from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note on Saturday, November 8th. Seven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Immunocore has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $61.00.</p>
<div class="lb-trans"><p>多位股票分析師最近對該股發佈了報告。摩根士丹利將 Immunocore 的目標價從 34.00 美元上調至 36.00 美元，並在 11 月 10 日的研究報告中給予該公司 “持平” 評級。Guggenheim 於 9 月 18 日星期四開始對 Immunocore 進行覆蓋。他們對該公司給予了 “中性” 評級。HC Wainwright 在 10 月 22 日星期三重申了 “買入” 評級，並對 Immunocore 的目標價設定為 100.00 美元。Weiss Ratings 在 10 月 8 日星期三的報告中重新發布了對 Immunocore 的 “賣出（e+）” 評級。最後，Wall Street Zen 在 11 月 8 日星期六的研究報告中將 Immunocore 的評級從 “持有” 上調至 “買入”。七位投資分析師對該股給予了買入評級，四位給予了持有評級，一位給予了賣出評級。根據 MarketBeat 的數據，Immunocore 的共識評級為 “適度買入”，平均目標價為 61.00 美元。</p>
</div><p><strong>Read Our Latest Report on Immunocore</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Immunocore 的最新報告</strong></p>
</div><h2>Immunocore Trading Down 3.2%</h2>
<div class="lb-trans"><h2>Immunocore 股價下跌 3.2%</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增長的股票分析師認為價格將翻倍</li>
</ul>
</div><p>The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -68.16 and a beta of 0.77. The company has a quick ratio of 5.97, a current ratio of 6.00 and a debt-to-equity ratio of 0.99. The firm's 50 day moving average is $35.06 and its 200 day moving average is $34.23.</p>
<div class="lb-trans"><p>該公司的市值為 19.7 億美元，市盈率為 -68.16，貝塔值為 0.77。該公司的速動比率為 5.97，流動比率為 6.00，債務股本比率為 0.99。該公司的 50 日移動平均線為 35.06 美元，200 日移動平均線為 34.23 美元。</p>
</div><p>Immunocore (NASDAQ:IMCR - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The company had revenue of $103.69 million for the quarter, compared to analysts' expectations of $137.29 million. Immunocore had a negative return on equity of 7.67% and a negative net margin of 7.70%.The firm's revenue was up 29.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.17 earnings per share. Equities analysts forecast that Immunocore Holdings PLC Sponsored ADR will post -0.94 earnings per share for the current year.</p>
<div class="lb-trans"><p>Immunocore（NASDAQ:IMCR - 獲取免費報告）最近於 11 月 6 日星期四發佈了季度財報。該公司報告每股收益（EPS）為 0.02 美元，超出市場共識預期的 -0.30 美元，超出幅度為 0.32 美元。該公司季度收入為 1.0369 億美元，而分析師預期為 1.3729 億美元。Immunocore 的股本回報率為 -7.67%，淨利潤率為 -7.70%。該公司的收入同比增長 29.2%。在去年同期，該公司每股收益為 0.17 美元。股票分析師預測 Immunocore Holdings PLC 贊助的 ADR 在本年度將發佈 -0.94 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Immunocore</h2>
<div class="lb-trans"><h2>Immunocore 的內部買賣</h2>
</div><ul>
<li>Institutions are Buying These 3 Stocks and Analysts Agree</li>
</ul>
<div class="lb-trans"><ul>
<li>機構正在購買這 3 只股票，分析師一致認為</li>
</ul>
</div><p>In related news, insider David M. Berman sold 22,532 shares of Immunocore stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a legal filing with the SEC, which is available at this link. 10.40% of the stock is owned by company insiders.</p>
<div class="lb-trans"><p>在相關消息中，內部人士 David M. Berman 於 9 月 12 日星期五出售了 22,532 股 Immunocore 股票。該股票以平均價格 35.67 美元出售，總價值為 803,716.44 美元。此次出售已在與 SEC 的法律文件中披露，文件可在此鏈接查看。10.40% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. GAMMA Investing LLC lifted its position in shares of Immunocore by 51.6% in the 3rd quarter. GAMMA Investing LLC now owns 914 shares of the company's stock valued at $33,000 after acquiring an additional 311 shares in the last quarter. DNB Asset Management AS lifted its holdings in shares of Immunocore by 6.4% in the third quarter. DNB Asset Management AS now owns 8,116 shares of the company's stock valued at $295,000 after purchasing an additional 488 shares in the last quarter. Virtus Investment Advisers LLC lifted its holdings in shares of Immunocore by 5.3% in the second quarter. Virtus Investment Advisers LLC now owns 12,472 shares of the company's stock valued at $391,000 after purchasing an additional 625 shares in the last quarter. Orion Porfolio Solutions LLC boosted its position in shares of Immunocore by 4.5% in the second quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock worth $752,000 after buying an additional 1,031 shares during the period. Finally, Assetmark Inc. grew its holdings in shares of Immunocore by 3.7% during the second quarter. Assetmark Inc. now owns 34,958 shares of the company's stock valued at $1,097,000 after buying an additional 1,248 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。GAMMA Investing LLC 在第三季度將其在 Immunocore 的持倉增加了 51.6%。GAMMA Investing LLC 目前擁有 914 股該公司股票，價值 33,000 美元，此前在上個季度增持了 311 股。DNB Asset Management AS 在第三季度將其在 Immunocore 的持倉增加了 6.4%。DNB Asset Management AS 目前擁有 8,116 股該公司股票，價值 295,000 美元，此前在上個季度增持了 488 股。Virtus Investment Advisers LLC 在第二季度將其在 Immunocore 的持倉增加了 5.3%。Virtus Investment Advisers LLC 目前擁有 12,472 股該公司股票，價值 391,000 美元，此前在上個季度增持了 625 股。Orion Porfolio Solutions LLC 在第二季度將其在 Immunocore 的持倉增加了 4.5%。Orion Porfolio Solutions LLC 目前擁有 23,965 股該公司股票，價值 752,000 美元，此前在此期間增持了 1,031 股。最後，Assetmark Inc. 在第二季度將其在 Immunocore 的持倉增加了 3.7%。Assetmark Inc. 目前擁有 34,958 股該公司股票，價值 1,097,000 美元，此前在上個季度增持了 1,248 股。84.50% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Immunocore Company Profile</h2>
<div class="lb-trans"><h2>Immunocore 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.</p>
<div class="lb-trans"><p>Immunocore Holdings plc 是一家商業階段的生物技術公司，專注於開發用於治療癌症、感染和自身免疫性疾病的免疫療法。該公司提供 KIMMTRAK，用於治療不可切除或轉移性葡萄膜黑色素瘤的患者。它還開發其他腫瘤學項目，包括正在進行 2/3 期臨牀試驗的 tebentafusp，用於治療晚期皮膚黑色素瘤。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另請參閲</h2>
</div><ul>
<li>Five stocks we like better than Immunocore</li>
<li>Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?</li>
<li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li>
<li>Dividend Capture Strategy: What You Need to Know</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
<li>What is a SEC Filing?</li>
<li>Marvell's Rally Extends: Data Centers and AMZN Chips Boost Shares</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票超過 Immunocore</li>
<li>資產配置：成功投資組合的關鍵。你在關注自己的投資組合嗎？</li>
<li>加密礦工會轉向 AI 嗎？關於 3 家關鍵參與者的最新消息</li>
<li>股息捕獲策略：你需要知道的事項</li>
<li>Salesforce 股票像彈簧一樣蓄勢待發，準備反彈</li>
<li>什麼是 SEC 備案？</li>
<li>Marvell 的反彈延續：數據中心和 AMZN 芯片推動股價上漲</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Immunocore Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Immunocore 嗎？</h2>
</div><p>Before you consider Immunocore, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Immunocore 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街評級最高和表現最佳的研究分析師及他們推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Immunocore 並不在名單上。</p>
</div><p>While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Immunocore 目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Immunocore（納斯達克股票代碼：IMCR）創下新的 1 年高點 - 以下是發生的情況